Top Dx Financial Planning Mistakes You Must Avoid | Diaceutics

Top Dx Financial Planning Mistakes You Must Avoid

May 24th, 2016

Top Dx Financial Planning Mistakes You Must Avoid

When it comes to financial planning in the pharmaceutical industry there are five common mistakes that must absolutely be avoided. To understand how to remedy these mistakes, it helps to realize that one is an overarching problem in pharma financial planning, and the other four are contributing problems to this. They are:

  1. Failing to carefully vary the annual strategy and budget each year
  2. Neglecting to select specific goals
  3. Using weak or using no analytics
  4. A lack of discipline in allocating budgets
  5. Failure to allocate sufficient budget for Dx strategy implementation

Failure to implement systems to enforce accountability and timeliness

The first item is the overarching problem. By attending to items 2 through 5 you will go far toward remedying the problem of sticking to stagnant financial strategies. It’s important to have a flexible and responsive method of creating your annual financial plan because there are many changes to the industry that will affect you each year. Health fads, environmental hazards and responses to them, and people’s behaviors are all subject to change. Further, new research may emerge affecting the medication prescribed by the physician. These are just a few of the reasons that you must take a careful look at your annual budget and resist the temptation to recycle the same plan year after year.

Goal Specificity

Hopefully, earnings goals can reasonably be aimed higher this year than last year. It will be necessary to take a close look at the market and discover where trends are leading, who is investing in what, and what innovations the research community has delivered. A degree of prescience may be required, but if you know the market, you’ll have it.

Key Analytics

Guessing is off the table. There is a host of analytic tools available for use today- and there are many services out there who specialize in pharmaceutical market analytics. It’s been said by specialists that there is no such thing as perfect guidance. But when your team is shooting in the dark, some guidance is better than none.

Accountability and Timeliness Systems

Assign specific tasks to specific team members with guidance according to actions and time constraints. Every complex project can be simplified by breaking it down and handling it in bits. So, it is wise to assign different parts of the financial plan to different members of your team. This will help to reevaluate accountability and scheduling in reviews.

Whether it’s fear or a lack of imagination that keep so many organizations from breaking away from previous financial plans, the truth is that the problem has reached epidemic proportions. That’s good news for those who manage to break the spell, as they will easily stand out from the rest- but bad news for those who fail to break away from worn out and overused financial planning patterns.

Diaceutics CTA FP

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn